On the 25th of April, the World Malaria Day 2022 took place. This year’s theme was “Harness innovation to reduce the malaria disease burden and save lives“, since the main goal of the World Health Organization (WHO) was to highlight the necessity of research and development for new therapeutic strategies to eradicate the disease. Today, malaria is entirely preventable and curable disease if the symptoms are recognized in earlier stages, but in some cases, it is unfortunately not possible. Therefore, the estimated number of new cases in 2020 was 241 million, and within that number there were 627 thousand malaria-related deaths in 85 countries. The region at highest risk is the sub-Saharan Africa, where more than two thirds of deaths were reported among the children under the age of 5. Despite the promising and steady advances in controlling the disease between 2000 and 2015, in recent years there was an evident set-back especially in the number of preventable deaths. What are the causes of this stagnation and what can be done to prevent the spread of this highly contagious disease?
The last topic in the series on medical research and clinical trials is related to studies on vaccines and, what better example to explain vaccines research than the recent Covid-19 pandemic. Similar to pharmaceutical products, vaccines trials occur in 3-4 phases (Phase I-III pre-marketing authorization and Phase IV after the vaccine is licensed).
This issue comes with yet another alumni interview. This time we wish to present to you Julia Hamblin-Trué, a pretty loyal alumni member and, as you’ll probably agree after getting to know her, a Swiss knife of Summer School of Science. Julia is currently an undergraduate student at CODE University of Applied Sciences in Berlin, where she studies Product Management. Her Summer School of Science journey started back in 2017 when she was a participant in S3++ camp. Continue reading and you’ll find out how her S3++ journey continued, where she is now and how she got there.